Glucosamine

Generic Name: Glucosamine

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₃NO_₅

CAS Number: 3416-24-8

Unique Ingredient Identifier: N08U5BOQ1K

Background: Osteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation. Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional benefits to nonsteroidal anti-inflammatory drugs treating the painful symptoms of OA. Glucosamine is commonly used over the counter as a treatment for arthritic joint pain, although its acceptance as a medical therapy varies due to contradictory and findings with unclear clinical significance during clinical trials. It is currently not approved as a prescription product by the FDA, but is widely available over the counter.

Indication: Glucosamine is generally used over the counter in the symptomatic treatment of osteoarthritis and joint pain, frequently combined with chondroitin sulfate and/or ibuprofen.

Associated Conditions: Back pain, Joint Pain, Osteoarthritis (OA), Osteoarthritis of the Knee, Articular inflammation

Clinical Trials

Glucosamine Sulphate Versus Ginger in Non-Surgical Periodontal Therapy

Phase 2

Completed

Conditions: Periodontal Pocket

Interventions: Drug: Glucosamine Sulfate
Drug: Ginger Oil

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-17

Lead Sponsor: Ain Shams University

Target Recruit Count: 30

Registration Number: NCT06200415

Locations: 🇪🇬
Ain Shams University, Cairo, Egypt

Prescription-grade Crystalline Glucosamine Sulfate Therapy in Erosive Hand Osteoarthritis

Completed

Conditions: Erosive Osteoarthritis of the Hand

Interventions: Drug: Glucosamine Sulfate

First Posted Date: 2022-02-14

Last Posted Date: 2022-03-04

Lead Sponsor: University of Siena

Target Recruit Count: 123

Registration Number: NCT05237596

Locations: 🇮🇹
Rheumatology Unit Azienda Ospedaliera Universitaria Senese, Siena, Italy

Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects

Not Applicable

Recruiting

Conditions: Joint Pain

Interventions: Drug: Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Drug: Collagen type II (40 mg/day)
Drug: Collagen type II (80mg/day)
Drug: Placebo
Drug: Collagen type II (120 mg/day)

First Posted Date: 2022-01-28

Last Posted Date: 2022-11-30

Lead Sponsor: Vedic Lifesciences Pvt. Ltd.

Target Recruit Count: 375

Registration Number: NCT05212259

Locations: 🇮🇳
Shalby hospital, Sūrat, Gujarat, India
🇮🇳
Shree Ashirwad Hospital, Dombivli, Maharashtra, India
🇮🇳
BLDEU Hospital and research center, Bijapur, Karnataka, India

and more 7 locations

A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study

Phase 3

Withdrawn

Conditions: Knee Osteoarthritis

Interventions: Drug: Placebos
Drug: glucosamine sulphate 1500mg and meloxicam 15mg
Drug: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg

First Posted Date: 2019-05-03

Last Posted Date: 2022-04-18

Lead Sponsor: Eurofarma Laboratorios S.A.

Registration Number: NCT03936192

Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis

Completed

Conditions: Hand Osteoarthritis

Interventions: Drug: Glucosamine Sulfate

First Posted Date: 2019-04-11

Last Posted Date: 2019-04-12

Lead Sponsor: University of Siena

Target Recruit Count: 108

Registration Number: NCT03911570

Locations: 🇮🇹
Rheumatology Unit Azienda Ospedaliera Universitaria Senese, Siena, Italy

Transdermal Delivery of Glucosamine to the Synovial Fluid of Male and Female With Knee Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Transdermal Glucosamine Cream

First Posted Date: 2018-11-16

Last Posted Date: 2018-11-16

Lead Sponsor: Lynk Biotechnologies Pte Ltd

Target Recruit Count: 240

Registration Number: NCT03743896

Locations: 🇸🇬
T&T Family Heath Clinic and Surgery, Singapore, Singapore

Therapeutic Approaches to Malnutrition Enteropathy

Phase 2

Completed

Conditions: Severe Acute Malnutrition

Interventions: Dietary Supplement: Colostrum high protein powder (Neovite)
Drug: N-Acetyl Glucosamine (GInNAC)
Drug: Budesonide
Drug: Teduglutide

First Posted Date: 2018-10-23

Last Posted Date: 2021-09-27

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 125

Registration Number: NCT03716115

Locations: 🇿🇼
Harare Central Hospital, Harare, Zimbabwe
🇿🇼
Parirenyatwa Hospital, Harare, Zimbabwe
🇿🇲
University Teaching Hospital, Nationalist Road, Lusaka, Zambia